Celltrion, Inc.
Financials
Valuation Metrics
Celltrion, Inc.'s Market Cap is ₩41.8T. At end of 2025 it was ₩40.1T. Ranked #17 of 2,421 in KR market (top 0.7%), #17 of 781 on KOSPI (top 2%), #2 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.9%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 41.82T KRW | KR#17/2,421 Sec#2/231 |
| Revenue | 4.90T KRW | KR#132/2,421 Sec#1/231 |
| Net Income | 1.58T KRW | KR#33/2,421 Sec#2/231 |
| Total Assets | 22.33T KRW | KR#72/2,421 Sec#1/231 |
| Net Assets | 17.35T KRW | KR#34/2,421 Sec#1/231 |
| Employees | 2,901 | KR#106/2,421 Sec#2/231 |
| Value | ||
| P/E | 26.45x | KR#1,274/2,421 Sec#76/231 |
| P/B | 2.41x | KR#2,022/2,421 Sec#153/231 |
| PEG | 0.12x | KR#442/2,421 Sec#22/231 |
| P/S | 8.54x | KR#2,251/2,421 Sec#159/231 |
| EV/EBITDA | 28.67x | KR#1,177/2,421 Sec#71/231 |
| FCF Yield | 1.54% | KR#1,095/2,421 Sec#75/231 |
| Profitability | ||
| ROE | 9.11% | KR#689/2,421 Sec#48/231 |
| ROA | 7.08% | KR#507/2,421 Sec#39/231 |
| Op. Margin | 31.65% | KR#52/2,421 Sec#12/231 |
| Revenue Growth | 30.64% | KR#383/2,421 Sec#38/231 |
| Earnings Growth | 222.61% | KR#226/2,421 Sec#12/231 |
| Financial Health | ||
| Debt Ratio | 28.71% | KR#555/2,421 Sec#62/231 |
| Total Debt | 3.74T KRW | KR#85/2,421 Sec#1/231 |
| FCF | 646.05B KRW | KR#48/2,421 Sec#2/231 |
| Cash | 1.12T KRW | KR#92/2,421 Sec#1/231 |
| Net Debt/EBITDA | 1.69x | KR#810/2,421 Sec#57/231 |
| Dividend | ||
| Div. Yield | 0.40% | KR#1,290/2,421 Sec#78/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | 11.95% | KR#547/2,421 Sec#33/231 |
| 1M Return | -7.37% | KR#1,962/2,421 Sec#160/231 |
| From 52W High | -24.85% | KR#382/2,421 Sec#22/231 |
| 1Y MDD | -32.70% | KR#332/2,421 Sec#25/231 |
| Trading | ||
| Volume | 241,280 shares | KR#420/2,421 Sec#25/231 |
| Trading Value | 43.48B KRW | KR#87/2,421 Sec#2/231 |
| Foreign Own. | 25.25% | KR#164/2,421 Sec#5/231 |
| Per Share | ||
| EPS | 6,797 KRW | KR#167/2,421 Sec#8/231 |
| BPS | 74,597 KRW | KR#185/2,421 Sec#11/231 |
Company Info
Celltrion, established in 1991, completed its KOSDAQ listing in 2005 and transferred to the Securities Market in 2018, building a unified corporate structure through the absorption merger of Celltrion Healthcare in 2023. It develops, produces, and sells antibody drugs using biotechnology and animal cell mass culture technology, possessing an 11-product portfolio. The company is strengthening its next-generation antibody drug pipeline through alliances and investments with global biotech companies. Celltrion is headquartered in Yeonsu-gu, Incheon Metropolitan City.